Product Description
Avatrombopag is used to treat thrombocytopenia (a low number of platelets [type of blood cell needed for blood clotting]) in people with chronic (ongoing) liver disease who are scheduled to have a medical or dental procedure to help prevent bleeding complications. It is also used to treat thrombocytopenia in people with chronic immune thrombocytopenia (ITP; an ongoing condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood) who were not helped with another treatment. Avatrombopag is in a class of medications called thrombopoietin (TPO) receptor agonists. It works by causing the body to produce more platelets. (Sourced from: https://medlineplus.gov/druginfo/meds/a618032.html)
Mechanisms of Action: TPO Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Orphan Drug - Thrombocytopenia *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | Ireland | Italy | Latvia | Lithuania | Luxembourg | Netherlands | Norway | Poland | Portugal | Romania | Russia | Saudi Arabia | Slovakia | Slovenia | Spain | Sweden | Switzerland | United Arab Emirates | United Kingdom | United States
Approved Indications: Thrombocytopenia
Known Adverse Events: Abdominal Pain | Headache | Pain Unspecified | Edema
Company: Eisai
Company Location: BUNKYO-KU TOKOYO 112 M0
Company CEO: Haruo Naito
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, France, Germany, Hungary, Japan, Poland, Russia, Turkey, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 7
Highest Development Phases
Phase 3: Purpura, Thrombocytopenic, Idiopathic|Thrombocytopenia
Phase 2: Digestive System Cancer|Gastrointestinal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| jRCT2031220005 | P3 |
Recruiting |
Thrombocytopenia|Purpura, Thrombocytopenic, Idiopathic |
2026-05-31 |
|
| 2020-003232-24 | P3 |
Active, not recruiting |
Thrombocytopenia|Purpura, Thrombocytopenic, Idiopathic |
2025-05-03 |
|
| ACT-GI | P2 |
Recruiting |
Thrombocytopenia|Gastrointestinal Cancer|Digestive System Cancer |
2025-03-30 |
|
| AVA-ITP-307 | P3 |
Active, not recruiting |
Thrombocytopenia|Purpura, Thrombocytopenic, Idiopathic |
2024-01-17 |